Ultragenyx Pharmaceutical Inc. business relationships
Companies named in Ultragenyx Pharmaceutical Inc.’s 10-K filed 2026-02-18, and public companies whose annual reports name Ultragenyx Pharmaceutical Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.1 / 10
- AI naming
- 100 / 100 Top 1% in its category
- Agent readiness
- 20 / 100
- AI adoption
- 0 / 100
Named in Ultragenyx Pharmaceutical Inc.’s annual report 11
“Please see "-License and Collaboration Agreements-Approved Products-Regeneron" for a description of our license agreement with Regeneron.” SEC filing
“Evkeeza is approved in the U.S., where it is marketed by our partner Regeneron Pharmaceuticals, or Regeneron.” SEC filing
“The Evkeeza drug substance is manufactured by Regeneron at their manufacturing facility in Rensselaer, New York and the drug product is manufactured by Baxter Pharmaceutical Solutions, LLC at their manufacturing facility in Bloomington, Indiana.” SEC filing
“Amendment No. 3 to Collaboration and License Agreement, effective September 29, 2017, between Ultragenyx Pharmaceutical Inc. and Kyowa Hakko Kirin Co., Ltd.” SEC filing
“Please see "-License and Collaboration Agreements-Clinical Product Candidates-REGENXBIO Inc." for a description of our license agreement with REGENXBIO Inc.” SEC filing
“Please see "-License and Collaboration Agreements-Clinical Product Candidates-REGENXBIO Inc." for a description of our license agreement with REGENXBIO Inc.” SEC filing
“Amendment No. 1, effective as of September 13, 2024, to the Supply Agreement between Ultragenyx Pharmaceutical Inc. and Kyowa Kirin, Inc.” SEC filing
“We sold our right to receive certain royalty payments from net sales of Crysvita in certain territories to RPI Finance Trust (an affiliate of Royalty Pharma) and OCM LS23 Holdings LP (an investment vehicle for Ontario Municipal Employees Retirement System, or OMERS.” SEC filing
“...past sought and may in the future seek funds through a sale of future royalty payments similar to our transactions with Royalty Pharma and OMERS or through collaborative partnerships, strategic alliances, and licensing or other arrangements, such as our transaction with Daiichi Sankyo Co., Ltd. and...” SEC filing
“The Mepsevii drug substance is manufactured by Rentschler Biopharma SE, or Rentschler, under non-exclusive commercial supply and services agreements.” SEC filing
“...ough collaborative partnerships, strategic alliances, and licensing or other arrangements, such as our transaction with Daiichi Sankyo Co., Ltd. and we may be required to relinquish rights to some of our technologies or product candidates, future revenue streams, research programs, and other product...” SEC filing
Companies whose annual reports name Ultragenyx Pharmaceutical Inc. 4
“| License Agreement by and between Abeona Therapeutics Inc. and Ultragenyx Pharmaceutical Inc., dated May 16, 2022 (incorporated by reference to Exhibit 10.3 of our Form 10-Q for the quarter ended June 30, 2022) |” SEC filing
“...aku for RGX-121 and RGX-111, and (iii) NAV Technology Platform license agreements with Rocket Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc. Zolgensma and Itvisma royalties earned under the Novartis License shall only be included in the Royalty Interest after full repayment of the applicab...” SEC filing
“First Amendment to Collaboration and License Agreement, dated May 20, 2025, between Mereo BioPharma 3 Limited and Ultragenyx Pharmaceutical Inc.” SEC filing
“...October 2020, the license agreement was amended such that we were required to pay the University of Washington $375 thousand in connection with the execution of the collaboration and license agreement ("the Collaboration Agreement") with Ultragenyx Pharmaceutical Inc. ("Ultragenyx") in October 2020.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.